Grindeks
JSC Grindex (branded as Grindex), or simply Grindeks, is an internationally operating Latvian pharmaceutical company with headquarters in Riga, Latvia. Its portfolio consists of original products, generics, and active pharmaceutical ingredients. It mostly focuses on cardiovascular, central nervous system, anti-cancer, and diabetes medicines. Grindex is the leading pharmaceutical manufacturer in the Baltic States. In 2021 Grindex imported products to more than 90 countries.
| Grindex | |
| Industry | Pharmaceuticals |
| Founded | 1946 |
| Headquarters | 53 Krustpils St, Riga , Latvia |
Key people | Kirovs Lipmans(Chairman of the Council), Juris Hmelnickis (CEO), Janis Romanovskis (Chief Finance and Administrative Officer), Andrejs Liberts, (Commercial director) |
| Products | Mildronate; Ftorafur |
Production output | Pharmaceuticals |
| Revenue | 187 million EUR (2020) |
| Owner | Liplat Holding, Ltd. |
Number of employees | 1498 (2021) |
| Subsidiaries | JSC Kalceks, JSC Tallinn Pharmaceutical Plant, HBM Pharma Ltd. |
| Website | www.grindeks.eu |
Grindex Group consists of JSC Grindex and its four subsidiaries — JSC Kalceks (Latvia), HBM Pharma Ltd. (Slovakia), JSC Tallinn Pharmaceutical Plant (Estonia) and Namu apsaimniekošanas projekti Ltd. (Latvia).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.